Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pioglitazone + clomiphene citrate
- Development stage
- Unknown
- Lead developer
- Pakistan Atomic Energy Commission General Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
pioglitazone + clomiphene citrate is a combination therapy investigated for the treatment of infertility in women with polycystic ovary syndrome (PCOS). Pioglitazone is a thiazolidinedione that acts as a potent agonist for the peroxisome proliferator-activated receptor gamma (PPAR-gamma), which improves insulin sensitivity and reduces hyperinsulinemia, common factors in PCOS-related ovulatory dysfunction. Clomiphene citrate is a selective estrogen receptor modulator (SERM) that acts as an estrogen antagonist in the hypothalamus, blocking negative feedback and stimulating the release of gonadotropins (FSH and LH) to induce ovulation. The combination is intended to enhance ovarian stimulation and improve pregnancy rates, particularly in patients who may be resistant to clomiphene monotherapy due to underlying insulin resistance. This specific regimen has been evaluated in clinical trials sponsored by PAEC General Hospital, Islamabad.
- Other names
- Pioglitazone (PIO) + Clomiphene citrate
02
Targets
ER (Estrogen receptor)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on pioglitazone + clomiphene citrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pioglitazone + clomiphene citrate.